Timber Creek Capital Management LLC Has $4.14 Million Stock Holdings in Novartis AG (NYSE:NVS)

Timber Creek Capital Management LLC boosted its holdings in shares of Novartis AG (NYSE:NVS) by 0.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,531 shares of the company’s stock after buying an additional 163 shares during the period. Timber Creek Capital Management LLC’s holdings in Novartis were worth $4,139,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its position in Novartis by 128.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 528,682 shares of the company’s stock valued at $51,554,000 after purchasing an additional 296,890 shares in the last quarter. World Investment Advisors LLC purchased a new position in shares of Novartis during the 3rd quarter valued at $30,063,000. Fisher Asset Management LLC increased its stake in shares of Novartis by 15.7% in the third quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock worth $196,225,000 after acquiring an additional 231,851 shares during the last quarter. Mediolanum International Funds Ltd purchased a new stake in shares of Novartis during the third quarter worth $24,096,000. Finally, ABC Arbitrage SA acquired a new stake in Novartis during the fourth quarter valued at $19,795,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Morgan Stanley initiated coverage on shares of Novartis in a report on Wednesday, February 12th. They issued an “underweight” rating for the company. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Novartis in a research report on Thursday, February 13th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $123.38.

Novartis Trading Up 1.2 %

Shares of NVS stock opened at $106.65 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. Novartis AG has a 1 year low of $92.35 and a 1 year high of $120.92. The firm’s fifty day simple moving average is $100.78 and its 200 day simple moving average is $108.20. The firm has a market capitalization of $217.99 billion, a P/E ratio of 18.14, a price-to-earnings-growth ratio of 1.68 and a beta of 0.58.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. As a group, sell-side analysts predict that Novartis AG will post 8.44 EPS for the current year.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.